Experts point out that getting sick before the completion of the two-dose vaccine program should not detract from the effectiveness of the product
new York- Last week, a series of headlines flooded social media. These headlines reported a COVID-19 case by a San Diego nurse. This is obviously worrying. The patient became ill about a week after receiving the first dose of Pfizer’s coronavirus vaccine. fall down.
However, experts say that the development of this disease during this period is not unexpected: it is well known that the protective effect of the vaccine will take at least a few weeks to develop. They pointed out that getting sick before completing the two-dose vaccine program should not reduce the effectiveness of Pfizer’s product, which has successfully entered the final stage of clinical trials.
Intensive care doctor Taison Bell reported that people who had not received the full dose of the vaccine were infected with COVID-19, “It’s really like saying someone came out in a storm without an umbrella and got wet.” At the University of Virginia. Bell received her first dose of Pfizer vaccine on December 15 and will receive her second dose soon.
The 45-year-old California nurse, known as Matthew W. in the ABC10 news report, received his first dose of Pfizer vaccine on December 18. According to news reports, six days later, he began to experience mild symptoms, including chills, muscle aches and fatigue. The day after Christmas, he tested positive for the virus.
Megan Ranney, a physician in the emergency room at Brown University, said this should not be a cause for concern. “Then what to do?” He responded to a Reuters article on the nurse’s condition in a tweet on Wednesday. “This is a two-dose vaccine.” Ranney received the first dose of Pfizer vaccine on December 18.
Lanni said in an interview that the nurse’s illness is news, which shows that this is not what was expected, and that there should be protective measures about a week after the first dose of the vaccine. But in fact, it’s not.
It takes at least a few days for the vaccine to be protective. Pfizer’s formula is designed around a molecule called messenger RNA or mRNA. Once injected, it enters human cells and instructs it to make coronavirus proteins called spikes. None of these ingredients are infectious or cannot cause COVID-19. But they act as imposters for the coronavirus, teaching the human body to recognize the real virus and resist it as soon as it enters.
It is believed that spike production occurred within a few hours of the first dose. But the corpse needs at least a few days to remember the material before it can unload the entire defensive arsenal to resist the virus. This time, immune cells are required to analyze the protein, make it mature, reproduce and enhance its reflex to identify spikes.
Pfizer’s clinical trial data indicate that the vaccine may begin to protect its recipients from disease about one to two weeks after the first dose. Another injection of mRNA three weeks after the first injection can help immune cells restore the most important characteristics of the virus, thus strengthening the protection process.
Ranney pointed out that the disease schedule of California nurses is very suitable for the vulnerable period after vaccination. It is also possible that you were infected with the virus before (or even earlier) you were vaccinated. If people have symptoms of COVID-19, they may begin to feel them two to 14 days after contracting the coronavirus (if any).
A similar situation occurred recently with Mike Harmon, a Kentucky auditor who tested positive for the virus one day after receiving the first unspecified coronavirus vaccine this week.
He said in a statement: “It seems that I might have been exposed to the virus unknowingly and was caught before or shortly after receiving the first dose of the vaccine on Monday.” Harmon reiterated his “full confidence in the vaccine.” , And as many people as possible need to receive the vaccine as soon as possible”.
Pfizer spokesperson Jerica Pitts pointed out that the protective effect of the vaccine was “significantly enhanced after the second dose, supporting the need for a two-dose series of vaccines.”
He said: “People may have contracted this disease before or after being vaccinated.”
When Pfizer was given the complete two-dose vaccine, it was found to be effective in preventing 95% of symptomatic COVID-19 cases. This number has become good news due to the rising trend of coronavirus cases. However, this makes it impossible for a small number of people to be protected after being vaccinated, Lenny said. “No vaccine is 100% effective.”
It is not yet known how the Pfizer vaccine effectively protects asymptomatic people from infection, or whether it will significantly reduce the ability of the virus to spread from one person to another. This means that even after receiving full vaccination, measures such as masks or social isolation are still essential.
Information collected by Pfizer during the final clinical trial indicates that the vaccine may provide at least some protection after receiving a single dose of the vaccine. But the purpose of this study is not to specifically test the effectiveness of a single injection treatment.
Krutika Kuppalli, an infectious disease physician at the University of South Carolina School of Medicine, said two of her colleagues tested positive shortly after taking the first medication. He said: “Given the rate of increase in cases, this does not surprise me.” Since the vaccine is not expected to have an immediate effect, it “should not be regarded as a vaccine failure.” Kuppalli received the first dose of the vaccine from Pfizer on December 15. He added that after consulting with medical staff, contracting COVID-19 between the two vaccines should not discourage anyone from receiving the second dose.
In recent weeks, more than 2.7 million people in the United States have received their first dose of vaccine from Pfizer or Moderna. Bell said that both vaccines consist of two doses of vaccines, and more and more people come into contact with them. Therefore, it is important to maintain good communication on how and when the vaccine works.
He said: “At present, we must adhere to the dose determined in the trial.” “This will allow us to obtain the maximum efficiency.”